Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chembio Diagnostics
Medford, New York, United States
- Ownership
- Private
- Employees
- ~337
- Development stage
- Other
01
Overview
Chembio Diagnostics commercializes multiple rapid point-of-care tests—most notably using its patented Dual Path Platform (DPP)—for HIV, syphilis, hepatitis C, Chagas, and Zika. Several products (e.g., DPP HIV-Syphilis) are FDA approved, CLIA waived, and CE marked. The company recently received FDA Breakthrough Device status for its DPP Syphilis TnT assay and SURE CHECK HIV self-test[4][7].
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- DeviceRapid immunoassay testImmunochromatographic test
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
BiosynexProciseDxQualigen Diagnostics
Beyond the preview
Go deeper on Chembio Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chembio Diagnostics.